NBTX vs URGN: stock comparison and AI forecast
Nanobiotix S.A. (NBTX) and Urogen Pharma Ltd. (URGN) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
NBTX Nanobiotix S.A.
- Market Cap
- $1.64B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
- NO CURRENT FORECAST
URGN Urogen Pharma Ltd.
- Market Cap
- $1.68B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- NBTX and URGN have similar market capitalizations ($1.64B and $1.68B).
- URGN turns -51.7% of its revenue into net income, against -215.7% for NBTX.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | NBTX | URGN |
|---|---|---|
| Market Cap | $1.64B | $1.68B |
| EPS | $-2.86 | – |
| Revenue/Share | $1.09 | $3.86 |
| FCF/Share | $-1.77 | $-3.26 |
Profitability & Margins
| Metric | NBTX | URGN |
|---|---|---|
| ROA | -148.0% | -38.6% |
| ROIC | – | -35.0% |
| Gross Margin | – | 91.8% |
| Operating Margin | -184.3% | -35.3% |
| Net Margin | -215.7% | -51.7% |
| EBT Margin | – | -52.0% |
| Tax Rate | – | 0.5% |
Financial Health
| Metric | NBTX | URGN |
|---|---|---|
| Current Ratio | 1.09x | 3.80x |
| Quick Ratio | – | 3.41x |
| Interest Coverage | – | -18.7x |
| Working Capital | $6M | $174M |
Cash Flow
| Metric | NBTX | URGN |
|---|---|---|
| Operating Cash Flow | -$84M | -$159M |
| Free Cash Flow | -$86M | -$159M |
| Capital Spending | -$2M | -$220K |
| FCF/Sales | -162.3% | -84.3% |
| CapEx/Sales | 3.1% | 0.1% |
Operational Efficiency
| Metric | NBTX | URGN |
|---|---|---|
| Asset Turnover | 0.69x | 0.75x |
| Receivables Turnover | – | 2.1x |
| Inventory Turnover | – | 0.6x |
| Fixed Assets Turnover | 10.2x | 316.1x |
| Days Sales Outstanding | – | 172 days |
| Days Inventory | – | 580 days |
| Payables Period | – | 365 days |
| Cash Conversion Cycle | – | 387 days |
Income Statement
| Metric | NBTX | URGN |
|---|---|---|
| Total Revenue | $53M | $189M |
| Operating Income | -$97M | -$67M |
| Net Income | -$114M | -$98M |
| R&D Expense | $90M | $61M |
| SG&A Expense | $59M | $177M |
| Cost of Goods Sold | – | $15M |
Dividend & Shareholder Information
| Metric | NBTX | URGN |
|---|---|---|
| Shares Outstanding | 48M | 49M |
NBTX vs URGN: stock comparison and AI forecast
Which is bigger, NBTX or URGN?
NBTX and URGN have similar market capitalizations ($1.64B and $1.68B).
Which one does Intratio's AI model rank higher, NBTX or URGN?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.